Porton Pharma Reports 10.4% Revenue Growth, 224‑Million CNY Loss in H1 2026
Porton Pharma’s first‑half 2026 results: revenue up 10.42% to 1.79 billion CNY, net loss widened to 224 million CNY, with strong growth in APIs and cell‑gene therapy. Click to see the full story.
2 minutes to read